Cardiac tumors medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Dj}} | {{CMG}}; {{AE}} {{Dj}} | ||
==Overview== | ==Overview== | ||
Most of the Cardiac tumors are treated with surgical management. Medical treatment has been used as adjuvant chemotherapy or in small isolated tumors. | |||
==Medical Treatment of Cardiac Tumors== | ==Medical Treatment of Cardiac Tumors== | ||
{| class="wikitable" | |||
|+ Cardiac Tumors Medical Management | |||
|- | |||
! Tumor || Treatment | |||
|- | |||
| '''[[Cardiac Lymphoma]]''' || Rituximab is an '''[[anti-CD20 monoclonal antibody]]''' that typically produces remission in a wide range of B-cell non-Hodgkin lymphomas. | |||
MOA: Activation of antibody-dependent, [[cell-mediated cytotoxicity]], [[complement-mediated lysis]], [[phagocytosis]] of antibody-coupled tumor cells, and activation of cell death appear to constitute its mode of action. | |||
|} | |||
Revision as of 00:11, 19 May 2022
|
Cardiac tumors Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cardiac tumors medical therapy On the Web |
|
American Roentgen Ray Society Images of Cardiac tumors medical therapy |
|
Risk calculators and risk factors for Cardiac tumors medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Template:Dj
Overview
Most of the Cardiac tumors are treated with surgical management. Medical treatment has been used as adjuvant chemotherapy or in small isolated tumors.
Medical Treatment of Cardiac Tumors
| Tumor | Treatment |
|---|---|
| Cardiac Lymphoma | Rituximab is an anti-CD20 monoclonal antibody that typically produces remission in a wide range of B-cell non-Hodgkin lymphomas.
MOA: Activation of antibody-dependent, cell-mediated cytotoxicity, complement-mediated lysis, phagocytosis of antibody-coupled tumor cells, and activation of cell death appear to constitute its mode of action. |